277 related articles for article (PubMed ID: 7820185)
1. Induction of lymphokine-activated killer (LAK) activity in canine lymphocytes with low dose human recombinant interleukin-2 in vitro.
Helfand SC; Soergel SA; Modiano JF; Hank JA; Sondel PM
Cancer Biother; 1994; 9(3):237-44. PubMed ID: 7820185
[TBL] [Abstract][Full Text] [Related]
2. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
Da Pozzo LF; Hough KL; Holder WD
Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) and lymphokine-activated killer (LAK) cell functions from healthy dogs and 29 dogs with a variety of spontaneous neoplasms.
Funk J; Schmitz G; Failing K; Burkhardt E
Cancer Immunol Immunother; 2005 Jan; 54(1):87-92. PubMed ID: 15693143
[TBL] [Abstract][Full Text] [Related]
5. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of interleukin-6-enhanced lymphokine-activated killer cell function.
Iho S; Shau HY; Golub SH
Cell Immunol; 1991 Jun; 135(1):66-77. PubMed ID: 2018984
[TBL] [Abstract][Full Text] [Related]
7. Change in peripheral blood lymphocyte count in dogs following adoptive immunotherapy using lymphokine-activated T killer cells combined with palliative tumor resection.
Mie K; Shimada T; Akiyoshi H; Hayashi A; Ohashi F
Vet Immunol Immunopathol; 2016 Sep; 177():58-63. PubMed ID: 27436446
[TBL] [Abstract][Full Text] [Related]
8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
Colquhoun SD; Economou JS; Shau H; Golub SH
J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
10. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
[TBL] [Abstract][Full Text] [Related]
11. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
12. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer.
Rayner AA; Grimm EA; Lotze MT; Chu EW; Rosenberg SA
Cancer; 1985 Mar; 55(6):1327-33. PubMed ID: 3871657
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-7 induces differential lymphokine-activated killer cell activity against human melanoma cells, keratinocytes, and endothelial cells.
Schadendorf D; Böhm M; Möller P; Grünewald T; Czarnetzki BM
J Invest Dermatol; 1994 Jun; 102(6):838-42. PubMed ID: 8006445
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxicity of interleukin 2-induced lymphokine-activated killer (LAK) cells against human leukemia and augmentation of killing by interferons and tumor necrosis factor.
Teichmann JV; Ludwig WD; Thiel E
Leuk Res; 1992; 16(3):287-98. PubMed ID: 1560676
[TBL] [Abstract][Full Text] [Related]
16. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo.
Hank JA; Weil-Hillman G; Surfus JE; Sosman JA; Sondel PM
Cancer Immunol Immunother; 1990; 31(1):53-9. PubMed ID: 2306756
[TBL] [Abstract][Full Text] [Related]
17. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2-activated lymphocytes from brain tumor patients. A comparison of two preparations generated in vitro.
Kruse CA; Mitchell DH; Lillehei KO; Johnson SD; McCleary EL; Moore GE; Waldrop S; Mierau GW
Cancer; 1989 Oct; 64(8):1629-37. PubMed ID: 2790675
[TBL] [Abstract][Full Text] [Related]
19. Depressed ability of patients with melanoma or renal cell carcinoma to generate adherent lymphokine-activated killer cells.
Sedlmayr P; Rabinowich H; Elder EM; Ernstoff MS; Kirkwood JM; Herberman RB; Whiteside TL
J Immunother (1991); 1991 Oct; 10(5):336-46. PubMed ID: 1790141
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
